InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,419.20
(
0.00%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.43
(
0.36%
)
Bitcoin
64,489.57
(
0.77%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 245534

Thursday, 03/16/2023 8:23:48 PM

Thursday, March 16, 2023 8:23:48 PM

Post# of 251721
PFE/Astellas—Xtandi phase-3 shows statsig-superior MFS* both as an addend to Lupron (compared to Lupron alone) and as monotherapy compared to Lupron in non-metastatic HSPC patients at high-risk for disease recurrence:

https://www.pfizer.com/news/press-release/press-release-detail/phase-3-study-shows-xtandir-enzalutamide-plus-leuprolide

The (secondary endpoint) OS data are not yet mature, but are trending positively for Xtandi + Lupron vs Lupron alone. The full dataset will be presented at an unspecified medical conference.

PFE booked $1.2B in Xtandi-alliance revenue in 2022 pursuant to its worldwide collaboration with Astellas that splits US profits 50/50 and pays PFE royalties on ex-US sales. Xtandi goes off-patent in the US in 2027.

*Metastasis-free survival (similar to PFS).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up